Bora inks $2.5B deal with drug discovery AI specialist Insilico

Insilico Medicine, an AI drug discovery specialist, has partnered with CDMO Bora Pharmaceuticals in a deal worth up to $2.5 billion, combining Insilico's Pharma.AI platform for target discovery and molecule optimisation with Bora's manufacturing and commercialisation capabilities. Insilico claims its platform generates preclinical candidates in 12-18 months versus the industry standard of 2.5-4 years, and has nominated 31 candidates since 2021, with 13 receiving IND approval. If Insilico's timeline claim holds (12-18 months to preclinical candidate), you're watching the economics of early-stage drug discovery get inverted overnight. CDMOs like Bora are now buying discovery capability rather than waiting for pharma companies to feed them molecules—that shift just proved repeatable (Lilly, Takeda, SK Biosciences, now Bora), which means the customer acquisition funnel for discovery AI is real.